Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant measles virus hemagglutinin protein vaccine
- Development stage
- Preclinical
- Lead developer
- MEVOX
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The recombinant measles virus hemagglutinin protein vaccine (rMeVH) is a novel recombinant protein subunit vaccine candidate developed by Mevox in collaboration with Johns Hopkins University and the Vaccine Research Center (NIAID/NIH). It consists of a recombinant dimeric measles virus hemagglutinin (H) protein. Designed as a safer alternative to the live-attenuated measles-mumps-rubella (MMR) vaccine, rMeVH is intended for populations who cannot receive live vaccines, such as pregnant women and immunocompromised individuals. In preclinical studies in rhesus macaques, intramuscular administration of rMeVH elicited robust neutralizing antibody titers and protected the animals from measles disease and systemic viral spread upon wild-type measles virus challenge.
- Other names
- rMeV vaccinerMeVH vaccinerecombinant dimeric measles virus hemagglutinin protein vaccinerecombinant measles protein vaccine
02
Targets
MV-H (Measles virus hemagglutinin protein)
Beyond the preview
Go deeper on recombinant measles virus hemagglutinin protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant measles virus hemagglutinin protein vaccine.